Samsung C&T, Samsung Electronics, and GRAIL, Inc. have entered into a binding Letter of Intent to collaborate strategically on introducing GRAIL’s Galleri multi-cancer early detection test to key Asian markets. As part of this agreement, Samsung C&T and Samsung Electronics will invest $110 million in GRAIL at a share price of $70.05. GRAIL is focused on detecting cancer early when it is most treatable.
Health Technology Insights: Lirio Appoints Inaugural Advisory Board to Drive the Company’s Next Phase of Growth
Jaywoo Kim, Executive Vice President of Life Science Business at Samsung C&T, emphasized that Samsung has long been committed to advancing biotechnology and improving quality of life. He views this partnership with GRAIL as a major step beyond just investment. It provides Samsung a strong entry point into cancer screening technology for South Korea and other Asian markets. Samsung and GRAIL plan to commercialize Galleri initially in South Korea, with possibilities to expand to Japan and Singapore. The tests will initially be processed in GRAIL’s clinical lab located in Research Triangle Park, North Carolina. Samsung C&T will lead efforts to promote adoption of the Galleri test in these regions.
Health Technology Insights: Freed Unveils EHR Push: One-Click AI Note Transfer Into Any Web-Based EHR
Sir Harpal Kumar, President of International Business and Biopharma at GRAIL, expressed enthusiasm about working with Samsung to bring multi-cancer early detection capabilities to Asia, starting in South Korea. He noted that Samsung’s investment strengthens GRAIL’s financial position and supports its progress toward reimbursement approvals in the United States and other international markets.
In addition to the investment, Samsung Electronics and GRAIL intend to explore further cooperation on projects such as genomic-lifestyle clinical research and integrating Samsung’s health data platforms with GRAIL’s clinical and genetic technologies. Hon Pak, Senior Vice President and Head of Digital Health at Samsung Electronics, highlighted how this collaboration fits into Samsung’s vision to enhance health outcomes for billions worldwide. He suggested that combining Samsung’s AI and digital health systems with GRAIL’s genetic data could offer users personalized health insights.
The collaboration and investment agreements are expected to be finalized by early 2026, with commercial operations to start soon after. Samsung C&T will act as the exclusive distributor of Galleri in South Korea, and possibly in Japan and Singapore, under terms that will be defined in the final contracts. This partnership marks a significant move toward expanding advanced cancer screening technologies throughout Asia, backed by both companies’ shared commitment to innovation and improved patient care.
Health Technology Insights: GSK and IQVIA Launch Local Vaccine Data for Public Health
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
